NGC Update Service: November 26, 2012 ► National Institute for Health and Clinical Excellence (NICE) ► Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer.

NGC Update Service: November 26, 2012

National Institute for Health and Clinical Excellence (NICE)

• Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer.